- Home
- WIA vs VTYX Comparison
WIA vs VTYX Comparison
Compare WIA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- VTYX
- Stock Information
- Founded
- WIA 2003
- VTYX 2018
- Country
- WIA United States
- VTYX United States
- Employees
- WIA N/A
- VTYX N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- WIA Finance
- VTYX Health Care
- Exchange
- WIA Nasdaq
- VTYX Nasdaq
- Market Cap
- WIA 186.8M
- VTYX 154.9M
- IPO Year
- WIA N/A
- VTYX 2021
- Fundamental
- Price
- WIA $8.09
- VTYX $2.08
- Analyst Decision
- WIA
- VTYX Buy
- Analyst Count
- WIA 0
- VTYX 4
- Target Price
- WIA N/A
- VTYX $11.33
- AVG Volume (30 Days)
- WIA 39.2K
- VTYX 1.9M
- Earning Date
- WIA 01-01-0001
- VTYX 02-25-2025
- Dividend Yield
- WIA 12.29%
- VTYX N/A
- EPS Growth
- WIA N/A
- VTYX N/A
- EPS
- WIA N/A
- VTYX N/A
- Revenue
- WIA N/A
- VTYX N/A
- Revenue This Year
- WIA N/A
- VTYX N/A
- Revenue Next Year
- WIA N/A
- VTYX N/A
- P/E Ratio
- WIA N/A
- VTYX N/A
- Revenue Growth
- WIA N/A
- VTYX N/A
- 52 Week Low
- WIA $7.56
- VTYX $1.67
- 52 Week High
- WIA $8.91
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- WIA 51.52
- VTYX 45.64
- Support Level
- WIA $7.94
- VTYX $1.83
- Resistance Level
- WIA $8.18
- VTYX $2.61
- Average True Range (ATR)
- WIA 0.08
- VTYX 0.18
- MACD
- WIA 0.02
- VTYX -0.03
- Stochastic Oscillator
- WIA 65.20
- VTYX 32.26
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.